Why Antares Pharma Stock Is Soaring Today

Antares Pharma Inc ATRS shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc HALO for $5.60 per share in cash, valuing Antares at approximately $960 million. 

The transaction was unanimously approved by both the Halozyme and Antares boards of directors and is expected to be immediately accretive to Halozyme's 2022 revenue and non-GAAP earnings. Halozyme expects the acquisition to accelerate top- and bottom-line growth through 2027.

The business combination aims to create a leading drug delivery and specialty product company. Antares is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies.

See Also: Why BriaCell Therapeutics Stock Is Surging Today

ATRS 52-Week Range: $3.11 - $4.63

According to data from Benzinga Pro, the stock was up 49.1% at $5.58 at press time.

Photo: Parentingupstream from Pixabay.